There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory serine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture.
This screening strategy coupled with our unique chemical architecture generates a powerful platform for mining the kinase inhibitor space. In conjunction with structure-guided design efforts, our approach has produced unique high-quality targeted therapy leads that are poised for optimization and advancement to provide new therapeutic options, particularly in oncology.
Vibliome’s research operations are located in Bozeman, Montana on the edge of Yellowstone National Park and in the midst of world class skiing, fly fishing, unsurpassed access to nature and Montana’s largest research university.View Open Positions
Vibliome Therapeutics, LLC, announced today that it has expanded its highly curated proprietary kinase inhibitor discovery library to more than 500 unique compounds. This library is built on a common chemotype the company is leveraging for the development of novel therapeutics targeting clinically relevant cell signaling pathways.Read More
Vibliome Therapeutics, LLC, announced that it closed a $16mm Series A round of financing to advance its proprietary technology supporting the development of small molecule therapeutics targeting clinically-relevant signaling pathways. Deerfield Management was the sole investor in the Series A financing round and will be providing operational support.Read More
Chief Executive Officer
Jauch Professor and Professor of Chemical and Systems Biology, of Developmental Biology and of Chemistry, Stanford University
Professor in the Department of Pharmacological Sciences and the Director of the Medicinal Chemistry Core of the Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York NY
Associate Professor of Medicine, Harvard Medical School; Director of Clinical Research, Massachusetts General Hospital Cancer Center, Boston, MA
Director, Termeer Center for Targeted Therapies & Investigational Cancer Therapeutics Program, and Program Director, Investigational Cancer Therapeutics Program, Massachusetts General Hospital Cancer Center, Boston MA
Chief Scientific Officer, Celtaxsys, Inc.
Associate Professor of Radiation Oncology and Biochemistry, Director of Clinical Innovation and Information Technology, Department of Radiation Oncology, University of Texas Southwestern, Dallas TX
Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine; Director, Division of Hematology and Medical Oncology, New York University Langone Health